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Background: The purpose of this study was to compare the change in depth of target volume and dosimetric
parameters between the supine and lateral decubitus positions for breast boost treatment with electron beam
therapy.
Methods: We analyzed 45 patients who were treated, between 2009–2010, with whole breast radiation (WBRT)
followed by a tumor bed boost in the lateral decubitius position. Tumor bed volume, distance from skin to the
maximal depth of the tumor bed, D90 (dose covering 90% of the tumor bed volume), maximal dose, electron
energy and doses to heart and lungs were compared. Additional variables of body mass index (BMI) and tumor
bed location were also analyzed to see if there was a benefit limited to any subgroup.
Results: Median BMI for the 45 patients treated was 30.6 (20.6-42.4). When comparing the supine scan to the lateral
decubitus scan, there was no significant difference in the tumor bed volume (p = 0.116). There was a significant
difference between depth to the tumor bed in the supine scan and lateral decubitus scan (p < 0.001). The mean
maximum doses and D90 between the two scans were 110.7 (100.0-133.0)% vs 106.1 (95.1-116.9)% (p < 0.05) and
93.9 (81.3-01.0-101.0)% vs. 98.2 (89.1-108.0)% (p = 0.004) respectively. There was no difference in dose delivered to
the lungs or heart between the two scans (p = 0.848 and p= 0.992 respectively). On subset analysis, there was a
difference in depth to tumor that was seen across all BMI classes, including normal (p≤ 0.001, overweight
(p≤ 0.001) and obese (p≤ 0.001). The majority of patients had a tumor in the upper outer quadrant (77.8%) and on
subset analysis, there was a significant difference in tumor bed volume (p < 0.01), depth to tumor (p < 0.01), tumor
bed coverage [D90] (p < 0.05), maximum dose (p < 0.05) and energy (p < 0.001) for this location.
Conclusions: Delivering a tumor bed boost in the lateral decubitus position reduces the distance to the tumor
bed allowing for a lower energy treatment to be used to treat breast cancer. It improves coverage and decreases
maximal dose to the target volume, all of which would help reduce skin morbidities and should be considered
for patients with upper outer quadrant disease, irrespective of BMI status.
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Breast-Conserving Therapy (BCT) progressed to be
widely accepted since the 1980s, when several rando-
mized trials showed similar survival rates for the patients
who received radical mastectomy and those who
received BCT. Breast-Conserving Therapy followed by
Whole Breast Radiation Therapy (WBRT) to treat stage
I or II breast cancer, has been shown to reduce the risk
of local recurrence [1-3]. The National Surgical* Correspondence: Beriwals@upmc.edu
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has shown a reduction in ipsilateral breast recurrence
from 39.2% to 14.3% when treating patients with BCT
followed by WBRT vs. BCT alone [1]. Since then, studies
have shown that an additional boost to the tumor bed
after WBRT can decrease the local recurrence rates and
failures [4-6]. The European Organisation for Research
and Treatment of Cancer (EORTC) 22881–10882 has
shown that relative risk reduction of local recurrence by
the boost in addition to WBRT was significant in all age
groups, while the absolute risk reduction at 10 years was
larger in younger patients (patients <40 years old).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cosmetic results. The cosmetic results were scored as
excellent to good in 86% of the patients receiving no
boost and in 71% of the patients receiving a boost.
Severe fibrosis at 10 years was 4.4% in patients receiving
boost verses 1.6% in patients receiving no boost. Apart
from the boost, other predictors of poor cosmetic out-
come were identified. In the nomogram developed by
Collette et al. [7] for predicting breast fibrosis following
a boost dose, the treatment factors such as higher dose,
photon or interstitial implantation, and energy of elec-
trons were found to be of significance.
There are several techniques that can be used to
deliver the breast boost including electron beam, photon
beam, or interstitial implantation with the electron beam
being the most common technique used. However, there
are limitations involved in using electron beam tech-
nique, given that the dose delivery to the distal surgical
bed may be limited by the depth of surgical bed or
patient’s body habitus. Different techniques have been
used including prone decubitus positioning and recently
the lateral decubitus positioning to treat the boost
volume [8]. In lateral decubitus positioning technique,
placing the patient in the lateral decubitus position with
the patient rotated over the uninvolved breast can result
in a reduction in the distance from the skin to the target
volume maximum depth, particularly in patients with a
body mass index (BMI)≥ 30 [9]. This may result in using
lower electron energy and ultimately decreasing the
fibrosis. In this study, the depth of target volume in the
lateral decubitus position was analyzed in association
with the corresponding changes in the dosimetric para-
meters and was compared with supine position to evalu-
ate the potential advantage of lateral decubitus position.
Methods
A retrospective study was conducted on 100 patients,
who had undergone WBRT followed by tumor bed
boost. Of these, 45 patients were treated in the lateral
decubitus position between 2009–2010 and were sub-
jects of the study. All these patients were originally trea-
ted with CT-based photon plan for whole breastTable 1 Dosimetric parameters for all patients
Mean (St. deviation) Original
Tumor Bed (cc) 31.2 (2.5-198.0)
Depth to Tumor (cm) 5.7 (3.0-9.0)
D90 (%) 93.9 (81.3-101.0)
Maximum Dose (%) 110.7 (100.0-133.0)
Lung V50 (%) 2.2 (0.0-14.4)
Heart Max (Gy) (N= 24) 4.6 (0.4-13.7)
Energy (Mev) 18 (12–20)external beam radiation therapy (WBRT) in the supine
position and underwent re-simulation in the lateral de-
cubitus position for boost treatment. A comparison of
the plan for electron boost was made between original
supine and lateral decubitus position scans. A lateral de-
cubitus scan was obtained 4 or 5 weeks after starting
WBRT. To make the lateral decubitus scan reproducible,
a customized vacuum bag was made. The dosimetric
parameters including surgical bed volume, distance from
skin to maximal depth of the surgical bed, D90 (the dose
covering 90% of the tumor bed volume), maximal dose,
electron energy used, and doses to the heart (if the left
breast was irradiated) and ipsilateral lung were recorded
in the supine and lateral decubitus scans. Additional
variables of BMI and tumor bed location were also ana-
lyzed to evaluate whether there was a benefit particular
to any subgroup.
Results
The median BMI for the 45 patients treated was 30.6
(20.6-42.4). Of this sample population, 24 had tumor in
the left breast, and the remaining 21 had tumor in the
right breast. Furthermore, 35 patients had tumor located
in the upper outer quadrant, seven had tumor in the
lower outer quadrant, two had tumor in the upper inner
quadrant, and one patient had tumor in the lower inner
quadrant. Median time between the supine and lateral
decubitus scans was 37 (28–62) days.
Results are summarized in Tables 1, 2, 3, 4. The mean
surgical bed volumes for the supine and lateral decubitus
scans were 31.2 cc (2.5-198) and 25.8 cc (3.01-277.39)
respectively, without a significant difference in the
volumes (p = 0.116) between the two scans. However,
there was a significant difference between maximum
depth of tumor bed in the supine scan and lateral
decubitus scan (p < 0.001), with mean values of 5.7 cm
(3.0-9.0) and 3.56 cm (1.1-6.4) respectively. The mean
energy used in the supine and lateral decubitus scan was
18 MeV (12–20) and 13.6 MeV (9–20), (p < 0.001)
respectively. The mean maximum doses and D90
between the two scans were 110.7% versus 106.1%








Table 2 Dosimetric parameters of patients with tumor
volume difference <3.0 cc between original and lateral
decubitus scans
Mean (St. deviation), N = 17 Original Lateral
decubitus
P-value
Tumor Bed (cc) 9.5 (5.0) 9 (5.4) 0.172
Maximum Depth of Tumor
Bed (cm)
5.2 (1.2) 3.2 (0.7) 0.000
D90 (%) 94.1 (5.0) 98.3 (6.0) 0.091
Maximum Dose (%) 110.5 (9.6) 105.5 (5.9) 0.118
Lung V50 (%) 0.52 (1.1) 0.71 (1.1) 0.479
Heart Max (Gy) (N= 10) 3.7 (4.0) 4.6 (4.3) 0.451
Energy (Mev) 16.5 (3.1) 12.7 (3.2) 0.000
Kannan et al. Radiation Oncology 2012, 7:163 Page 3 of 5
http://www.ro-journal.com/content/7/1/163There was no difference in dose delivered to the lungs
or heart between the two scans (p = 0.848 and p = 0.992
respectively) [Table 1].
To account for changes in surgical bed volume
between the two scans, plan was separately evaluated
among 17 patients, for whom the change in the surgical
bed volume was less than 3.0 cc [Table 2]. There
remained a significant difference in maximal depth of
the tumor bed between the supine and lateral scans
measuring 5.2 cm (3.7-7.6) versus 3.2 cm (1.8-4.3)
respectively (p < 0.001). The mean energy used in the
supine and lateral decubitus scan was also significantly
Different (p < 0.001).
On subset analysis, there was a significant difference
seen in maximum depth to tumor bed across all BMI
categories, including normal (p < 0.001), overweight
(p ≤ 0.001), and obese (p < 0.01) [Table 3]. Because the
majority of patients had a tumor in the upper outer
quadrant (77.8%), a subset analysis of this region was
conducted and showed a significant difference in tumorTable 3 Dosimetric parameters based on BMI class
Parameter (Mean) Position BMI < 25 p-valu
Tumor Bed (cc) Original 15.7 0.155
Lat. Decub. 15.8
Depth to rumor (cm) Original 4.8 0.000
Lat. Decub. 2.8
D90 (%) Original 95.5 0.922
Lat. Decub. 95.7
Maximum Dose (%) Original 110.9 0.160
Lat. Decub. 103.9
Lung V50 (%) Original 4.3 0.808
Lat. Decub. 3.8
Heart Max (Gy) Original 6.9 0.437
Lat. Decub. 5.46
Energy (Mev) Original 15.5 0.242
Lat. Decub. 11.1bed volume (p < 0.01), maximum depth of tumor bed
(p < 0.01), tumor bed coverage [D90] (p < 0.05), max-
imum dose (p < 0.05) and electron energy used
(p < 0.001) between the two scans [Table 4].
Discussion
Boost dose after whole breast radiation therapy improves
local control at the cost of decreased cosmesis. The
factors that predict poor cosmetic results using electron
beam are dosage and higher energy [7]. In our series, re-
simulation of selected patients in lateral decubitus
position for breast boost treatment resulted in decreas-
ing the maximum distance from the skin to the sur-
gical bed, which facilitated the use of lower electron
energies and decreased maximal dose to the target vol-
ume [Figure 1]. These two gains have the potential to
improve cosmetic results.
Moreover, some patients with supine scan had max-
imal depth of surgical bed to more than 6 cm, which
was reduced significantly in lateral decubitus position.
These patients were not suitable for electron beam boost
and would have to be treated with conformal photon
beams. Photon beam techniques increase the integral
dose to breast in addition to increasing the volume of
breast tissue treated to the prescribed dose. This has
shown to result in higher likelihood of poor cosmetic
results in EORTC trial.
Study by Ludwig et al. [9] on 231 patients who under-
went re-simulation in the lateral decubitus position has
shown that the lateral decubitus positioning reduces the
distance from skin to maximal target volume depth in
all patients. Average depth reduction by repositioning
was 2.12 cm, allowing for an average electron energy
reduction of approximately 7 MeV. Furthermore, mean
skin entrance dose was reduced from about 90% toe BMI 25-30 p-value BMI >30 p-value
36.9 0.935 33.4 0.094
36.3 25.3
5.2 0.001 6.3 0.000
3.4 3.9
95.1 0.592 92.7 0.001
97.2 108.1
112.2 0.069 109.9 0.121
106.0 106.8
2.1 0.342 1.5 0.791
2.9 1.6
5.2 0.584 2.8 0.304
4.4 4.4
16 0.001 18.3 0.001
12.5 15.0







Tumor Bed (cc) 24.6 (24.2) 17.9 (21.8) 0.007
Depth to Tumor (cm) 5.7 (1.7) 3.4 (1.0) 0.000
D90 (%) 93.8 (4.7) 97.5 (5.5) 0.024
Maximum Dose (%) 110.7 (7.6) 106.0 (5.6) 0.022
Lung V50 (%) 1.8 (3.1) 2.1 (3.9) 0.517
Heart Max (Gy) (N= 19) 4.0 (3.6) 4.5 (3.8) 0.588
Energy (Mev) 16.8 (3.2) 13.0 (3.7) 0.000
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supine position, 146 (63.2%) of the patients would not
have the target volume covered by the distal 90% isodose
line of the maximum electron energy available at their
institution. Of the patients studied, 14 (6%) experienced
moist desquamation in the boost field at the end of
treatment. Average BMI of these patients was 30.4
(17.8–50.7). BMI greater than 30 was associated with
more depth reduction by repositioning and increasedFigure 1 Representative beam arrangement, beam energy and covera
patients. (A) 12 MeV beam energy resulted in an adequate coverage in th
needed to reach an adequate coverage when patient A in supine position
(C) 16 MeV beam energy resulted in an adequate coverage in the lateral de
an adequate coverage of the surgical bed when patient B in supine positiorisk of moist desquamation. These results were validated
in our study. Moreover, the maximal dose to the target
volume was also reduced with this technique, which
results in a better homogeneity. In addition, reposition-
ing provides a flat surface for optimum electron dosim-
etry, with an electron plane perpendicular to the surface.
In our study, patients were grouped based on body
mass index (BMI), and the analysis showed a significant
difference between supine and lateral decubitus scans in
term of maximum depth of tumor bed for all BMI
classes. In contrast, the study by Ludwig et al. [9]
reported that BMI above 30 was associated with an
increased risk of moist desquamation and a more depth
reduction by lateral decubitus repositioning. The author
suggested that the low moist desquamation rate in the
boost field with lateral decubitus positioning implies that
the boost treatment is well tolerated in patients with
high BMI, who would have a higher risk of toxicity with
conventional boost plan. This difference can be attribu-
ted to the fact that in Ludwig’s series this technique was
used selectively (9.4% of all patients who had boost radi-
ation therapy) and there may have been selection bias inge in lateral decubitus versus supine positioning in two different
e lateral decubitus position in patient A. (B) 20 MeV beam energy was
. 90% isodose line-14.4 Gy -was highlighted to review the coverage.
cubitus position in patient B. (D) 20 MeV beam energy did not result in
n. 90% isodose line-14.4 Gy -was highlighted to review the coverage.
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BMI. In contrast, at our institution this technique is
used in about 45% of the patients who need boost. On
subgroup analysis we found that lateral decubitus posi-
tioning would result in a shorter maximum depth to the
tumor bed, better D90, lower D-max, and allowing the
usage of lower electron energies in patients with upper
outer quadrant tumors. However, specific comments
cannot be made regarding any difference between patients
with different quadrant tumors, given the small number
of patients with disease in other quadrants. It is also im-
portant to highlight that in patients with significant ser-
oma, the re-simulation can account for changes in its size
over time and, therefore, result in a better boost plan, tak-
ing into account the new breast anatomy. Moreover, it is
important to mention that electron energy is one of many
factors that determines cosmetic outcome. These other
factors may include surgical technique, total radiation
dose and fraction size, radiation technique and any gen-
etic predisposition to late side effects.
Conclusions
In conclusion, using the lateral decubitus positioning for
breast boost treatment in selected patients results in re-
ducing the maximum depth to tumor bed, which facili-
tates the use of lower electron energy and increases the
likelihood of using boost via electron beam technique. It
also helps to reduce the maximal dose and improve the
target volume coverage (Figure 1). These improvements
can lessen the acute skin reactions and also help reduce
the fibrosis, thus improving the cosmetic results. Patients
with upper outer quadrant tumors may benefit more
from lateral decubitus positioning than other patients.
Therefore, it is important to choose patients for re-
simulation when the benefit of this technique is maxi-
mized based on the above-mentioned factors. Future
directions would include analyzing the clinical outcome
in patients treated in lateral decubitus position, particu-
larly in terms of late effects and cosmetic results.
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